CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy, specifically aromatase inhibitors or selective estrogen receptor degraders or modulators, have significantly improved outcomes for advanced estrogen receptor-positive (ER<sup>+</sup>) breast cancer; however, therapeutic resistance remains a primary cause of mortality. The gene discussed is CYP19A1; the disease is breast carcinoma.